1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Contribution of dopamine receptors to periaqueductal gray-mediated antinociception

Contribution of dopamine receptors to periaqueductal gray-mediated antinociception

  1. Gradient
    Psychopharmacology, 2009, Vol.204(3), pp.531-540
    Paul J. Meyer & Michael M. Morgan & Laura B. Kozell & Susan L. Ingram

    Abstract
    Rationale Morphine relieves pain, in part, by acting on neurons within the periaqueductal gray (PAG). Given that the PAG contains a subpopulation of dopamine neurons, dopamine may contribute to the antinociceptive effects mediated by the PAG.
    Methods This hypothesis was tested by measuring the behavioral and electrophysiological effects of administering dopamine agonists and antagonists into the ventrolateral PAG (vPAG). An initial histological experiment verified the existence of dopamine neurons within the vPAG using dopamine transporter and tyrosine hydroxylase antibodies visualized with confocal microscopy.
    Results Microinjection of cumulative doses of morphine into the vPAG caused antinociception that was dose- dependently inhibited by the dopamine receptor antagonist α-flupenthixol. α-Flupenthixol had no effect on nocicep- tion when administered alone. Injection of the dopamine receptor agonist (−) apomorphine into the vPAG caused a robust antinociception that was inhibited by the D2 antagonist eticlopride but not the D1 antagonist SCH- 23390. The effects of dopamine on GABAA-mediated evoked inhibitory post-synaptic potentials (eIPSCs) were measured in PAG slices. Administration of met-enkephalin inhibited peak eIPSCs by 20–50%. Dopamine inhibited eIPSCs by approximately 20–25%. Administration of α- flupenthixol (20 μM) attenuated eIPSC inhibition by dopamine but had no effect on met-enkephalin-induced inhibition.
    Conclusions These data indicate that PAG dopamine has a direct antinociceptive effect in addition to modulating the antinociceptive effect of morphine. The lack of an effect of α-flupenthixol on opioid-inhibition of eIPSCs indicates that this modulation occurs in parallel or subsequent to inhibition of GABA release.

    Discussion Thread